Catherine M. Diefenbach, MD

Catherine M. Diefenbach, MD, discusses polatuzumab vedotin (Polivy) plus obinutuzumab (Gazyva) and lenalidomide (Revlimid) in patients with follicular lymphoma.

Catherine M. Diefenbach, MD, assistant professor, Department of Medicine, NYU Langone Medical Center, discusses a phase I study with an expansion cohort examining the combination of ipilimumab and brentuximab vedotin for the treatment of patients with relapsed/refractory Hodgkin lymphoma.

Research and development in lymphomas are proliferating at such an accelerated pace that the promise of biomarker-driven targeted therapies is moving closer toward reality.

Catherine M. Diefenbach, MD, assistant professor, medicine (hematology and medical oncology), Perlmutter Cancer Center at NYU Langone, explains antibody drug conjugates (ADCs)